Your English writing platform
Discover LudwigSuggestions(1)
Exact(1)
Moreover, for variants with MAFs of 10% or greater, our study had >80% power to identify variants conferring a 1.3-fold increase in risk.
Similar(59)
In node negative cases, where the need for additional markers of response is greatest, our study shows that low ERβ2 mRNA levels are significantly related to worse outcome; as the cases in this subgroup analysis was small, a larger study of node negative patients is warranted.
In comparison to the study by Mc Nally et al., the overall duration of stay as well as the difference in length of stay was greater in our study between 'deficient' and 'not deficient' children despite having similar incidence rates as in their study.
In these studies, stretching was reported to be much greater than our study (more than 40%).
Disease control rate was also greater in our study (65.7%) than in the pivotal trial (41.1%).
The true extent of severe GAS infections in the LTCF population is likely greater than our study estimates.
Third, perfusate flow through the lung's capillary bed was greater in our study (300 vs 150 ml/min).
Also, the capecitabine pretreatment rate was greater in our study (90.7%%) compared with the rate reported in the EMBRACE study (73 %).
The incidence of hypogonadism among patients with type 2 diabetes was significantly greater in our study than observed in studies cited above.
For instance, the proportion of immunosuppressed patients was noticeably greater in our study and in that of Widmer et al. than that of Lee et al [ 21, 25].
Thus, it can be argued that the information content was significantly greater in our study than the one conducted by Heller et al. In our study, other heuristics and biases appeared to be independent of level of training.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com